Effects of dapagliflozin on body composition and liver tests in patients with non-alcoholic steatohepatitis associated with type 2 diabetes mellitus: A prospective, open-label, uncontrolled study
Conclusions Dapagliflozin was associated with improvements in body composition, most likely a reduction in visceral fat, which occurred together with improvements in liver tests and metabolic variables in patients with NASH associated with T2DM. Clinical trial registration: UMIN000023574
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research
More News: Alcoholism | Clinical Trials | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Forxiga | Insulin | Laboratory Medicine | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | SGLT2 Inhibitors | Study | Urology & Nephrology